Company Overview and News
KUALA LUMPUR (July 25): Small capitalised (small caps) stocks have the potential to generate returns the long run despite having underperformed so far this year, according to CIMB Research.
7216 5703 4405 7246 8079 7035
KUALA LUMPUR: CCK Consolidated Holdings Bhd, which has been recording a double-digit earnings growth in the last couple of financial years, is confident of repeating the feat for the current year ending Dec 31, 2018 (FY18).
CCK Consolidated Holdings Bhd (July 6, 90 sen) Maintain add with an unchanged target price (TP) of RM1.09: There’s 82 fund managers and analysts during CIMB Consumer Day last Wednesday. CCK Consolidated Holdings Bhd participated in the event and was represented by its managing director John Tiong Chiong Hiiung. There were no surprises from the meeting, with most discussions centred on: i) CCK Consolidated’s background and operations; ii) expansion plans across its integrated supply chain, especially in the retail segment; and iii) the supply-demand dynamics of poultry products in East Malaysia.
CCK Consolidated Holdings Bhd (June 12, 95.5 sen) Maintain add with an unchanged target price (TP) of RM1.09: CCK Consolidated Holdings Bhd’s share price went ex-bonus issue on Monday following the issuance of 315.4 million new bonus shares. The bonus issue also came with one-for-two new warrants at a strike price of 90 sen.
KUALA LUMPUR: JF Apex Research expects Fitters Diversified Bhd , Datasonic Group Bhd , Cypark Resources Bhd , Benalec Holdings Bhd and CCK Consolidated Holdings Bhd to be among the stocks to watch on Thursday.
5190 5216 9318 5184 7035
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...